Swiss pharma company, Basilea, receives FDA Qualified Infectious Disease Product designation for fungal drug, isavuconazole

PRESS RELEASE Basilea Pharmaceutica Ltd. announced Thursday that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive More...